RANBP2
RANBP2 (E3 SUMO-protein ligase RanBP2) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Hepatocellular carcinoma, Renal cell carcinoma and 5 more.
Overview
E3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates. Binds single-stranded RNA (in vitro).
Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.85, affected pathway 0.76, genetic association 0.10, somatic mutation 0.94). IntOGen calls it a driver in 7 cohorts (1 activating, 5 loss-of-function), covering Renal Clear Cell Carcinoma, Hepatocellular Carcinoma, Lung Squamous Cell Carcinoma, Neuroblastoma, Paraganglioma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · RANBP2 (E3 SUMO-protein ligase RanBP2) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Hepatocellular carcinoma, Renal cell carcinoma and 5 more.
- 1 · What it is
RANBP2 (E3 SUMO-protein ligase RanBP2) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Hepatocellular carcinoma, Renal cell carcinoma and 5 more.
- 2 · What goes wrong in cancer
E3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates.
- 3 · How drugs use it
No product in this corpus aims at RANBP2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:9848 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49792 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000153201 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: melanoma 0.52, skin cancer 0.55, breast cancer 0.52, lung cancer 0.59 (GraphQL API, CC0)); IntOGen RANBP2 (driver in 7 cohorts (Act 1, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
E3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates. Binds single-stranded RNA (in vitro). May bind DNA. Component of the nuclear export pathway. Specific docking site for the nuclear export factor exportin-1. Location: Nucleus; Nucleus membrane; Nucleus, nuclear pore complex; Nucleus envelope (UniProt). Locus 2q13 (HGNC).
- Lung cancer: Open Targets association 0.59 with lung cancer (MONDO_0008903)
- Hepatocellular carcinoma: IntOGen driver in 2 cohorts (HCC)
- Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
- Pheochromocytoma and paraganglioma: IntOGen driver in 1 cohort (PGNG)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Breast cancer: Open Targets association 0.52 with breast cancer (MONDO_0007254)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"RANBP2" OR ABSTRACT:"RANBP2" OR TITLE:"RAN binding protein 2" OR ABSTRACT:"RAN binding protein 2" OR TITLE:"E3 SUMO-protein ligase RanBP2" OR ABSTRACT:"E3 SUMO-protein ligase RanBP2" OR TITLE:"NUP358" OR ABSTRACT:"NUP358" OR TITLE:"ADANE" OR ABSTRACT:"ADANE" OR TITLE:"ANE1" OR ABSTRACT:"ANE1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RANBP2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetARHGEF12
Shares Clear cell renal cell carcinoma, Lung cancer (all types), Skin cancer (all types), Renal cell carcinoma.
- TargetCLTC
Shares Clear cell renal cell carcinoma, Lung cancer (all types), Renal cell carcinoma, Hepatocellular carcinoma.
- TargetPTPRK
Shares Clear cell renal cell carcinoma, Skin cancer (all types), Renal cell carcinoma, Breast cancer (all types).
- TargetCACNA1D
Shares Lung cancer (all types), Skin cancer (all types), Renal cell carcinoma, Hepatocellular carcinoma.
- TargetCLTCL1
Shares Lung cancer (all types), Skin cancer (all types), Hepatocellular carcinoma, Breast cancer (all types).
- TargetAFF4
Shares Lung cancer (all types), Skin cancer (all types), Hepatocellular carcinoma, Breast cancer (all types).
- TargetMAPK1
Shares Lung cancer (all types), Skin cancer (all types), Hepatocellular carcinoma, Breast cancer (all types).
- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.